**Supplementary figure 1. A Consolidated Standards Of Reporting Trials (CONSORT) style diagram showing the patients and eyes included in the analysis.**

Total of 157 eyes of 148 patients received first aflibercept injection for neovascular age- related macular degeneration between 1st September 2013 and 28th of February 2014.

8 eyes of 8 patients excluded due to loss of follow-up (no OCT data available for additional 19 eyes of 18 patients at the time of analysis). 1 eye of 1 patient excluded due to recurrence of pre- exciting intraocular inflammation

Total of 148 eyes of 139 patients included in visual acuity analysis of year 1 outcomes with 138 eyes of 130 patients included in analysis of OCT imaging

17 eyes of 16 patients excluded due to loss of follow-up (no OCT data available for additional 14 eyes of 13 patients at the time of analysis)

Total of 131 eyes of 123 patients included in visual acuity analysis of year 2 outcomes with 124 eyes of 117 patients included in analysis of OCT imaging

23 eyes of 21 patients excluded due to loss of follow up (no OCT data available for additional 24 eyes of 22 patients at the time of analysis)

Total of 108 eyes of 102 patients included in visual acuity analysis of year 3 outcomes with 100 eyes of 95 patients included in analysis of OCT imaging

14 eyes of 14 patients excluded due to loss of follow up (no OCT data available for additional 6 eyes of 6 patients at the time of analysis)

Total of 94 eyes of 89 patients included in visual acuity analysis of year 4 outcomes with 88 eyes of 83 patients included in analysis of OCT imaging